Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173518 · ClinicalTrials.gov registry record · Phase 1
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
A Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by Autolus Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT06173518 is a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Autolus Limited. The registered enrollment target is 30 participants, above the 24-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (25% higher). The trial reports 8 study locations across 4 states.
The verdict
NCT06173518, a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Autolus Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).
Conditions Studied
Interventions
- BIOLOGICAL AUTO1
Study Locations (8)
Other
- Hospital Vall d'Hebron - Barcelona
- Hospital Nino Jesus - Madrid
- Great Ormond Street Hospital for Children NHS Foundation Trust - London
- Royal Manchester Children's Hospital - Manchester
- Great North Children's Hospital - Newcastle upon Tyne
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Methodist Children's Hospital - San Antonio
Utah
- Primary Children's Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173518
The ClinicalTrials.gov registry entry for NCT06173518 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (25% higher). The listed sponsor is Autolus Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AUTO1 is the first listed.
NCT06173518 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT06173518 about?
NCT06173518 is a clinical study titled "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)". This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Ho...
What is the current status of trial NCT06173518?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-16. Estimated completion is 2027-11.
What conditions does trial NCT06173518 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06173518?
The interventions under investigation include: AUTO1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06173518?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173518 being conducted?
This trial has 8 study locations across Pennsylvania, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
ACTIVE NOT RECRUITING · Phase 1
-
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
RECRUITING · Phase 2
Explore more on PlainTrial
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
All registered trials for this condition
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.